FDA should require clinical trials and unique names for all biosimilars
In the wake of the landmark Supreme Court decision, Americans should consider the Affordable Care Act’s implications beyond the individual mandate and other politically divisive provisions. Specifically, the healthcare legislation contains language that will enable imitative versions of biotech drugs to be approved and sold in the United States. Now that the legislation has been […]